Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03325881

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial

Official title:
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Hyperkinesis
Clinical Trial Details
NCT number NCT03325881
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date December 9, 2017
Completion date June 7, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT03260205 - Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) Phase 3
Withdrawn NCT03546400 - Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD. Phase 4
Completed NCT02917109 - LearningRx Cognitive Training for ADHD N/A
Completed NCT02248948 - Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children N/A
Recruiting NCT01750307 - The Relationship of Essential Fatty Acids to Adult ADHD: The OCEAN Study (Oils and Cognitive Effects in Adult ADHD Neurodevelopment) N/A
Recruiting NCT06170996 - Internet-Assisted Behavioral Parent Training Intervention for Children With Attention Deficit Hyperactivity Disorder N/A
Completed NCT00735371 - Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 3
Withdrawn NCT03580005 - A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD. Phase 4
Completed NCT02578030 - Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD Phase 1
Completed NCT02574273 - Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program) N/A
Completed NCT02257216 - Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD) N/A
Recruiting NCT04943796 - A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life
Recruiting NCT04634006 - Home-Based tDCS in Children With ADHD: A Randomized, Sham-Controlled tDCS and fNIRS Study N/A
Active, not recruiting NCT02908802 - Probiotic Supplement as Treatment for Students With ADHD N/A
Completed NCT02604407 - Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) Phase 3
Completed NCT05870605 - Drug Use Study With Intuniv® in European Countries
Terminated NCT03481959 - Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Phase 3
Terminated NCT03638466 - Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder Phase 2
Completed NCT03709940 - Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT02795637 - Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction Phase 1